Clinical Efficacy of Istradefylline for Depression in Parkinsonâs Disease

@article{Ito2018ClinicalEO,
  title={Clinical Efficacy of Istradefylline for Depression in Parkinson{\^a}s Disease},
  author={H. Ito and Shigeru Fukutake and Sanae Odake and Junya Kawada and S. Iwanaga and Tetsumasa Kamei},
  journal={Journal of Neurology and Neuroscience},
  year={2018},
  volume={9}
}
  • H. Ito, Shigeru Fukutake, +3 authors Tetsumasa Kamei
  • Published 2018
  • Medicine
  • Journal of Neurology and Neuroscience
  • Background: Parkinson’s disease (PD) is a common movement disorder with a wide range of non-motor symptoms. Depression is one of these symptoms; however, its pathomechanism and management remains to be elucidated. We evaluated of istradefylline (ISD), a first selective adenosine A2A receptor antagonist, for the treatment of depression in PD. Method: This was an open-labeled, prospective study that enrolled 15 PD patients (Men 8, Women 7) with motor fluctuations who fully filled UK PD society… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 15 REFERENCES
    Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
    • 171
    Differences between Istradefylline Responders and Non-Responders in Parkinson’s Disease
    • 1
    • Open Access
    Systematic review of levodopa dose equivalency reporting in Parkinson's disease
    • 2,234
    • Open Access
    Parkinson’s disease: clinical features and diagnosis
    • 3,176
    • Open Access
    The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review.
    • 1,640
    • Highly Influential
    • Open Access
    Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease
    • 126
    • Open Access